Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

JayMac Pharmaceuticals Introduces EnLyte with Delta Folate: A Safe, Natural, & Complete Prescription Therapy For Depression
  • USA - English


News provided by

JayMac Pharmaceuticals, LLC

Feb 04, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

EnLyte With Delta Folate
EnLyte With Delta Folate

Sunset, Louisiana (PRWEB) February 04, 2014 -- Louisiana-based pharmaceutical company, JayMac Pharmaceuticals LLC, announces the introduction of EnLyte with Delta Folate. This is the first advanced generation folate prescription containing the optimal combination of three forms of folate, as well as B-vitamin metabolites, all proven effective in the dietary management and treatment of mild, moderate, and severe depression.

EnLyte is the natural, safe agent that finally addresses the root cause of depression rather than symptomatic relief.

Post this

Over 120 million people worldwide are afflicted with depression, but until now current prescription options fell short in solving this common problem. Serious side effects, drug interactions, and cost are just a few of the reasons the introduction of EnLyte into the natural pharmaceutical market is the answer to this large unmet need. EnLyte contains Delta Folate: a combination of L-Methylfolate Magnesium, Folinic Acid, and Folic Acid, plus all of the refined metabolites and minerals needed to optimize the brain's production of neurotransmitters, the chemicals deficient in depression.

EnLyte is a welcome addition to this market, at a time when leading authorities are endorsing the use of folates. Lawrence Ginsberg, MD, Red Oak Psychiatry and leading authority on depression research and treatment states, "Folate therapy is the essential cornerstone in the treatment of all patients afflicted with depression." Furthermore, both the American Psychiatric Association (APA) Guidelines and The American Journal of Psychiatry recommend the use of folate supplementation in depression.

Recent research has uncovered the clear link between genetics and depression, and a more complete natural alternative was needed. According to Andrew Farah, MD, High Point Division of UNC,"70% or more of us have a genetic basis for depression: an inability to produce the necessary neurotransmitters, especially in times of stress, and this is because B vitamins are needed in those chemical reactions, and we are unable to break down B vitamins or folate taken in from over-the-counter preparations or diet."

EnLyte is designed to supply all the brain-ready metabolized ingredients necessary to get to the root cause of depression, without the common side effects associated with typical antidepressants. "That's the #1 reason most people don't complete their recommended therapy-they don't like the side effects," states Dr. Farah. Because it contains natural ingredients, the side effects of this new agent are similar to placebo, and there are no drug interactions for patients or physicians to be concerned about. It's also third-party certified gluten-free. In fact, EnLyte is so safe, it has approval for use in pregnant and lactating women: "I highly recommend the use of EnLyte in women who are pregnant or planning to become pregnant." Dr. Ginsberg states.

New research suggests that the combination found in EnLyte is also effective in reducing Homocysteine (HCY), an amino acid found in the body, that has been linked to the development of depression, Alzheimer's Disease, stroke/vascular disease, and birth defects. EnLyte is a prescription therapy, recognized by most insurance companies nationwide, with plans to expand globally. T owny Robinson, CEO/JayMac Pharmaceuticals and co-inventor of EnLyte: "Exhaustive research with the Psychiatric medical community went into developing this new choice for depression. We've worked hard scientifically to provide a more complete, more effective, and more affordable option than was currently available."

About EnLyte
EnLyte is the first and only prescription folate therapy containing L-Methylfolate Magnesium, Folinic Acid, and Folic Acid, and all the necessary B-vitamin metabolites, in optimal doses, to completely address the remethylation and transsulfuration cycles and reduce Homocysteine.EnLyte is indicated for adjunct or monotherapy in mild, moderate, and severe depression, and is pregnancy category A for use in pregnant and lactating women.

About JayMac
JayMac Pharmaceuticals, LLC is a Sunset, Louisiana-based pharmaceutical company gaining interest with the introduction of EnLyte into the psychotropic and psychiatric market.

Angela Hall, JayMac Pharmaceuticals, LLC, http://www.EnlyteRx.Com, +1 850-602-1617, [email protected]

Modal title

EnLyte: Advanced Generation Folate Therapy
EnLyte: Advanced Generation Folate Therapy
EnLyte: Advanced Generation Folate Therapy

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.